OTC Contraceptive Pill Who Will Pay?

OTC Contraceptive Pill Who Will Pay?

The Arrival of the First Over-the-Counter Birth Control Pill

The first over-the-counter birth control pill, Opill (norgestrel), is set to arrive in drug stores in early 2024, marking a significant milestone in women’s reproductive health. However, as excitement builds around this new contraceptive option, questions about cost and insurance coverage have begun to arise.

The U.S. Food and Drug Administration recently approved Opill for preventing pregnancy without a prescription. Still, the pill’s maker, Perrigo, has yet to announce its price. Additionally, only six states currently require coverage of some over-the-counter birth control methods, including California, Maryland, New Jersey, New Mexico, New York, and Washington¹.

Affordability is a key factor in ensuring widespread access to birth control, including Opill. Victoria Nichols, the project director of Free the Pill, a coalition advocating for over-the-counter birth control pills, emphasizes that all forms of birth control should be fully covered by insurance in private and public plans². Currently, there is a federal policy that requires most private health insurance plans and Medicaid expansion programs to cover FDA-approved prescription contraceptive methods without a co-pay. However, there isn’t a federal requirement for nonprescription birth control methods just yet³.

To address potential access issues that Opill’s arrival may bring, researchers at the Kaiser Family Foundation (KFF) have conducted interviews with various stakeholders from private insurance plans, state Medicaid programs, and chain pharmacies in states that already require coverage of over-the-counter contraceptives⁴. Their findings shed light on the need for a seamless process when it comes to obtaining Opill through insurance plans.

The current system is primarily designed to cover prescription drugs, not over-the-counter options. Consequently, several issues and a lack of uniformity in billing practices arise, leading to confusion among key players⁵. Michelle Long, a senior policy analyst for Women’s Health Policy at KFF, highlights the importance of ensuring a straightforward process for consumers. She suggests that some private health plans may require individuals to pay for Opill at the cashier and then seek reimbursement from their plan⁶.

• Can antihypertensives reduce dementia risk?
• Premenstrual disorders linked to early menopause risk.
• What do lipids reveal about health and aging?

As these findings indicate, there is a need to improve awareness and education about the accessibility of over-the-counter contraceptives. The states that have already implemented benefits for such contraceptives are being viewed as trailblazers, but further efforts are needed to inform the public about this available benefit. Raising awareness may require additional funding and resources⁷.

Moreover, there is a significant role for pharmacists to play in facilitating the access and use of over-the-counter contraceptives. Don Downing, a clinical professor at the University of Washington School of Pharmacy, emphasizes the need for pharmacists to be aware that there are no age restrictions or parental consent requirements for Opill, unless imposed by the state⁸.

Another challenge lies in developing a nationally accepted claims processing system for pharmacists dispensing over-the-counter contraceptives. Streamlining this process could involve creating a universal dummy National Provider Identifier (NPI) to ensure smooth transactions. An NPI is a unique identification number used by healthcare providers to transmit health information⁹.

Alternatively, states could issue standing orders, which assert that pharmacists are fulfilling a pre-authorized request rather than prescribing the product. With standing orders, pharmacists would not need to enter claims information and would be protected from liability related to prescribing¹⁰.

Dr. Christine Gilroy, Chief Medical Officer at Express Scripts, stresses the importance of appropriately reimbursing pharmacists and minimizing the administrative burden associated with claims submission. This would allow pharmacists to focus on counseling patients and providing additional healthcare services, such as administering vaccines, rather than spending excessive time on administrative tasks¹¹.

In conclusion, the imminent arrival of Opill, the first over-the-counter birth control pill, presents an exciting development for individuals interested in convenient and accessible contraception. However, challenges around the cost and insurance coverage of over-the-counter contraceptives remain. Efforts must be made to ensure affordable access to these options, spreading awareness about the benefits and streamlining the process for pharmacists and consumers alike. By addressing these issues, we can empower individuals in their reproductive choices and foster a greater sense of control over their own healthcare.

References